CHESTERBROOK, Pa.-Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on innovative therapies for peripheral nerve injuries, today announced that it will present key interim results from the ongoing Phase 2 NEUROFUSE study at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, September 19-21 in Minneapolis, Minnesota. The presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial , has been named a Top 10 Paper and will be presented by David Brogan, MD, at Washington University during the Scientific Papers session on Thursday, September 19.
The original text of this announcement, written in the source language, is the official version that is authentic. Translations are offered solely for the convenience of the reader and must refer to the original language text, which is the only legally valid one.
Contacts
For more information about the NEUROFUSE study or Neuraptive Therapeutics, Inc. contact:
IR@neuraptive.com
+1-484-787-3203
